Finland has pledged to be carbon neutral by 2035. Helsinki’s pledge is set for 2030. Most organizations and states have made pledges that materialize decades away. Finland is therefore leading the way in these important commitments, crucial to fight the existential threat of climate change. Constant innovation, coupled with rapid commercialization, are key to the success of these ambitious goals. Great challenges abound, and these are coupled with numerous opportunities for profitable business outcomes for Finnish companies – opportunities that are not limited to Finland but applicable around the globe.
The MIT Industrial Liaison Program and the MIT Startup Exchange, in collaboration with Aalto University, are conducting a one-day symposium at the Dipoli center in the heart of the university campus. MIT and Aalto University faculty and startups, as well as representatives from Finnish industry, will discuss the business and technology challenges needed to further accelerate sustainable innovation. Launching and commercializing these innovations quickly will ensure that Finnish companies and institutions establish a leadership role in the crucial decades ahead.
As our keynote presentation, Prof. Carlo Ratti will discuss his team’s project, Helsinki’s Hot Heart, award winner of the 2021 Helsinki Energy Challenge. The project is an innovative and transformative energy storage system to provide district heating to the city. The MIT-Aalto Symposium will be an opportunity for the Finnish business community to interact directly with Prof. Ratti on this venture, intimately linked to life in Helsinki. Participants from the business community will also be able to engage with other faculty presenters, startups and with each other, an unusual occurrence in the past two years.
MIT Professional Education and Aalto Executive Education will also offer opportunities for continued engagement and learning for the Finnish corporate community.
AI Driven Bloodless Blood Tests Sean (Shunsuke) Matsuoka, Co-Founder & COO, GPx GPx: https://gpx.ai/
In an aging society, the number of heart failure patients is increasing, making the prevention of readmissions and reduction of medical costs critical issues. Remote monitoring using invasive implantable devices has proven effective in reducing heart failure readmissions, but its use remains limited.
To address this, GPx has developed an algorithm that non-invasively predicts signs of heart failure exacerbation. This algorithm was created using clinical trial data from monitoring 245 heart failure patients over 6 months to a year at eight facilities, including the Mayo Clinic in the U.S. The algorithm links digital biomarker data with vital blood tests (NT-proBNP and creatinine) to achieve high-precision prediction and early medical intervention.
Additionally, with a grant of 1.2 billion yen provided through AMED, we are collaborating with the National Cerebral and Cardiovascular Center (Dr. Chisato Izumi) to conduct a clinical trial involving 400 patients starting April 2025. The trial will be conducted at the National Cerebral and Cardiovascular Center, Kyoto University, Kobe University, and Kochi University.
Furthermore, at this year's MIT Japan Conference, we will unveil a groundbreaking point-of-care (POC) potassium testing device for the first time. At the conference, we aim to explore the feasibility of applying our technology to other conditions (such as kidney failure, pulmonary arterial hypertension, and cardio-oncology) and to assess the potential for providing algorithm-based services for heart failure patients within Japan.
Leading critical environment air quality management company looks for startups in two applications to address market needs resulting from COVID-19.
1. Airborne particulate matter counting and identification
2. New Air Disinfection and Monitoring Technology
Yet-Ming Chiang, Cofounder & Chief Scientist, 24M Rick Feldt, President, 24M
The 2024 MIT Health Science Technology Conference will highlight broad and transformative trends in biology and healthcare, including early-stage discovery, immune cell responses, diagnostics, clinical capabilities, process development, rapid and continuous manufacturing, robotics and automation, and sustainability, all enhanced by artificial intelligence and machine learning technologies. Leading MIT researchers and MIT-connected startups will showcase these advances and discuss their implications for improving human health.
James Gado - Welcome
Caleb Harper - Academic Innovator